Videos

3 KOLs are featured in this series.

Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency.

3 KOLs are featured in this series.

Panelists discuss how recent phase 3 trial data from PERSEUS, IsKia, and GMMG HD7 are shaping their approach to induction and consolidation therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, particularly focusing on the incorporation of CD38 antibodies into upfront treatment regimens and the potential shift from triplet to quadruplet therapies based on these pivotal trial findings.

Carrie Koenigsfeld, PharmD, FAPhA, discusses her experience with concerns and perceptions contributing to RSV vaccine hesitancy among older adults, such as safety, efficacy, necessity, awareness, and cost, and she explores how pharmacists can effectively counsel patients and caregivers about RSV vaccines while tailoring communication strategies to educate older adults with low health literacy.

3 KOLs are featured in this series.

Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings

3 KOLs are featured in this series.

Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.

3 KOLs are featured in this series.

Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.

Carrie Koenigsfeld, PharmD, FAPhA, discusses the CDC’s recommendation for an RSV vaccine for all adults aged 75 years and older, as well as those aged 60 to 74 years at increased risk, and outlines the conditions that elevate the risk for severe illness, including the implications of severe illness, such as hospitalization, long-term effects, complications, comorbidities, and mortality, while also comparing how RSV infection affects older vs younger adults.

3 KOLs are featured in this series.

Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.